For the quarter ending 2025-09-30, CLNN made $15,000 in revenue. -$8,776,000 in net income. Net profit margin of -58506.67%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | 15,000 | 27,000 | 81,000 | 82,000 |
| Cost of revenue | 0 | 0 | 20,000 | 17,000 |
| Research and development | 3,513,000 | 3,514,000 | 1,481,000 | 5,718,500 |
| General and administrative | 2,150,000 | 2,377,000 | 2,656,000 | 3,290,000 |
| Total operating expenses | 5,663,000 | 5,891,000 | 4,157,000 | 9,025,500 |
| Other income (expense), net | - | - | - | -250 |
| Loss from operations | -5,648,000 | -5,864,000 | -4,076,000 | -8,943,500 |
| Interest income | 40,000 | 62,000 | 81,000 | 234,500 |
| Loss on extinguishment of notes payable | - | - | - | -53,500 |
| Interest expense | 649,000 | 679,000 | 608,000 | 880,000 |
| Change in fair value of common stock warrant liabilities | 1,728,000 | 515,000 | -2,510,000 | 781,500 |
| Issuance costs for common stock warrant liabilities | - | - | - | 39,250 |
| Change in fair value of derivative liabilities | -797,000 | -439,000 | 1,147,000 | -94,750 |
| Loss on initial issuance of equity | - | - | - | -524,250 |
| Change in fair value of clene nanomedicine contingent earn-out liability | 0 | 0 | - | 17,666.667 |
| Change in fair value of initial stockholders contingent earn-out liability | 0 | 0 | - | 2,333.333 |
| Research and development tax credits and unrestricted grants | 5,000 | 16,000 | 195,000 | 152,000 |
| Total other income (expense), net | -3,129,000 | -1,555,000 | 3,325,000 | -3,371,000 |
| Net loss before income taxes | -8,777,000 | -7,419,000 | -751,000 | -12,314,500 |
| Income tax expense | 0 | 0 | - | 0 |
| Net loss | -8,777,000 | -7,419,000 | -751,000 | -12,314,500 |
| Unrealized loss on available-for-sale securities | 0 | 0 | - | - |
| Foreign currency translation adjustments | 1,000 | 63,000 | 15,000 | -103,500 |
| Unrealized gain (loss) on available-for-sale securities | - | - | - | -2,000 |
| Total other comprehensive income | 1,000 | 63,000 | 15,000 | -105,500 |
| Comprehensive loss | -8,776,000 | -7,356,000 | -736,000 | -12,420,000 |
| Net loss per share basic and diluted (in dollars per share) | -0.85 | -0.78 | -0.09 | -1.695 |
| Weighted average common shares used to compute basic and diluted net loss per share (in shares) | 10,284,674 | 9,523,592 | 8,824,673 | -3,013,444 |
Clene Inc. (CLNN)
Clene Inc. (CLNN)